Morgan Stanley analyst Drew Ranieri maintains Avanos Medical (NYSE:AVNS) with a Underweight and raises the price target from $26 to $28.
Morgan Stanley Maintains Underweight on Avanos Medical, Raises Price Target to $28
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.